Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T Therapy in Relapsed/Refractory Hematopoietic and Lymphoid Malignancies
NCT03121625Phase 1Unknown
- Sponsor
- Senlang Bio
- Start
- Dec 2016
- Primary completion
- Dec 2018
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in leukemia, lymphoma and multiple myeloma (MM), sponsored by Senlang Bio. Primary endpoint: Tumor load up to 24 months. Status: unknown.
02
Conditions
leukemialymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT03121625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03121625.